Tuesday, April 23, 2019 3:21:22 PM
My broker shows 29.1M OS, which most likely doesn't include the 9M+ being issued currently.
Good news I see is this month alone MBRX has new 20M+ in cash and while the earlier offering price was $1.00, the second was 1.60 and 1.75. I've been in development bio that sold shares for pennies to raise funds. Here MBRX was able to raise their share price 60% in less than a month and sell more shares at the higher price to raise cash.
I take that as a very good sign LT as to what their data is showing.
Good news I see is this month alone MBRX has new 20M+ in cash and while the earlier offering price was $1.00, the second was 1.60 and 1.75. I've been in development bio that sold shares for pennies to raise funds. Here MBRX was able to raise their share price 60% in less than a month and sell more shares at the higher price to raise cash.
I take that as a very good sign LT as to what their data is showing.
Recent MBRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 12:30:15 PM
- Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:00:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 12:00:58 PM
- Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks • GlobeNewswire Inc. • 05/13/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 01:30:19 PM
- Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits • GlobeNewswire Inc. • 05/12/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:45:12 PM
- Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin • GlobeNewswire Inc. • 05/08/2026 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 12:25:26 PM
- Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026 • GlobeNewswire Inc. • 04/23/2026 12:25:00 PM
- Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting • GlobeNewswire Inc. • 04/21/2026 12:36:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 03:40:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/15/2026 04:15:07 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/14/2026 09:26:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/14/2026 08:56:35 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 08:01:09 PM
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout • GlobeNewswire Inc. • 03/23/2026 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:35:12 PM
- Moleculin to Present at 38th Annual ROTH Conference • GlobeNewswire Inc. • 03/17/2026 01:05:00 PM
- Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study • GlobeNewswire Inc. • 03/11/2026 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 07:58:05 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 07:09:49 PM
